Chronic kidney disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• STAT3 1
• AKT 0
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• MAPK 0
• STING 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• JAK 0
• IL-1 1
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

24 of 4,752 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R01

  Mobile Strategy for Improving Eye Health of Kidney Patients Treated with Dialysis (SIGHT)

  University of Washington· Seattle, United States· US$1,383,760 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · K08

  Natural killer T cells in acute cardiorenal syndrome

  Oregon Health & Science University· Portland, United States· US$160,584 awarded in fiscal year 2026· until Jul 2031

• NIH NIDDK · R01

  The Interaction between Food Craving and Food Choice in Humans: A Computational Intracranial Electrophysiological Study

  Icahn School of Medicine at Mount Sinai· New York, United States· US$854,983 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  mRNA Splicing in Podocyte Biology and Glomerular Disease

  State University New York Stony Brook· Stony Brook, United States· US$755,725 awarded in fiscal year 2026· until Jun 2030

• NIH NIDDK · U01

  Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report

  Healthpartners Institute· Bloomington, United States· US$1,542,828 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,500,000· until Mar 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finland· EU contribution €4,273,568· until Jan 2031· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,693,628· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, France· EU contribution €1,498,100· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, United Kingdom· EU contribution €325,435· until Feb 2029

10 of 1,529 running projects, newest first. Listed amounts together: US$840.6m + €145.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Updated 12 Nov 2026

  “Recruitment temporarily paused.”Registry text, quoted unchanged. Source

• Suspended

  Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

  NCT04523727· Keryx Biopharmaceuticals· Updated 10 Nov 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  CommunityRx-Kidney Health

  NCT07237295· University of North Carolina, Chapel Hill· Updated 5 Nov 2026

  “Unanticipated operational challenges. No safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Novo Nordisk A/S· Updated 4 Nov 2026

  “Interim futility analysis showed primary endpoint not achieved”Registry text, quoted unchanged. Source

• Terminated

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· Alexion Pharmaceuticals, Inc.· Updated 29 Oct 2026

  “The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.”Registry text, quoted unchanged. Source

• Terminated

  Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CKD

  NCT05018845· The Foundation for Orthopaedics and Regenerative Medicine· Updated 20 Oct 2026

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source

• Withdrawn

  Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

  NCT07786571· Sun Yat-sen University· Updated 16 Oct 2026

  “The study was withdrawn because the protocol was revised and would be replaced by an updated study design, prior to participant enrollment.”Registry text, quoted unchanged. Source

• Terminated

  Solv Multi-Pass Hemodialysis System In-Center Clinical Study

  NCT07216885· Mozarc Medical US LLC· Updated 1 Oct 2026

  “Due to funding the study has been stopped. All subjects enrolled have completed the follow-up and have exited the study.”Registry text, quoted unchanged. Source

• Withdrawn

  Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

  NCT06995144· Sarfez Pharmaceuticals, Inc.· Updated 28 Sept 2026

  “No participants enrolled”Registry text, quoted unchanged. Source

• Withdrawn

  A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

  NCT07223502· Sarfez Pharmaceuticals, Inc.· Updated 22 Sept 2026

  “No recruitment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Intradialytic Benson's Relaxation Technique in Patients With Chronic Kidney Disease

  NCT07935980· Cairo University· Source

• The Effect of Intradialytic Exercise on Postural Abnormalities

  NCT07720401· Pardis Specialized Wellness Institute· Source

• Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5

  NCT06901960· Peking University First Hospital· Source

• A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

  NCT07024823· AstraZeneca· Source

• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Boehringer Ingelheim· Source

• A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

  NCT07931547· Novo Nordisk A/S· Source

• Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Boehringer Ingelheim· Source

• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Boehringer Ingelheim· Source

• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

  NCT07775846· Huijie Zhang· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 23
• Cohort Studies 556
• Genome-Wide Association Study 79

• Genome-wide CRISPR screens identify shared and context-specific regulators of podocyte resistance to oxidative injury.

  Ren Fail, Oct 2026

• SnRNA-seq and genome-wide CRISPR screening define the complete transcriptional trajectory and functional drivers of podocyte stress.

  Cell Mol Life Sci, Jul 2026

• Integrative machine learning and CRISPR/Cas9 analysis reveals the role of APOE in lipid metabolism-associated kidney fibrosis.

  Mol Med, Jul 2026

• Targeting LncRNAs with CRISPR/Cas9 for Kidney Therapeutics: A Review.

  Int J Biol Macromol, Dec 2025

• Targeting LncRNA MEG3 to modulate ER stress and autophagy: A CRISPR/Cas9-based strategy in AKI-to-CKD transition.

  Exp Cell Res, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.